Subjects treated, or anticipated to be treated, with a calcineurin inhibitor (because concomitant use of sirolimus and a calcineurin inhibitor increases the risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy [HUS/TTP/TMA]).
History of hemolytic-uremic syndrome.
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura
Intolerance of protocol agents as follows:\r\n* Known or presumed intolerance of gemcitabine, vorinostat or sorafenib\r\n* Experienced any of the following toxicities with prior gemcitabine administration (if given): capillary leak syndrome, posterior reversible encephalopathy, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, unexplained dyspnea or other evidence of severe pulmonary toxicity, or severe hepatic toxicity
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura
History of thrombotic microangiopathy, hemolytic-uremic syndrome, or thrombotic thrombocytopenic purpura
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura.
History of microangiopathic hemolysis, thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS)
Underlying renal disease with a high risk of disease recurrence in the transplanted kidney, including:\r\n* Focal segmental glomerulosclerosis (FSGS)\r\n* Type I or II membranoproliferative glomerulonephritis\r\n* Hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura
Presently with or a history of acute promyelocytic leukemia (APML), idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic uremic syndrome (HUS)
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura
